Advisor Information
Christine Cutucache
Presentation Type
Poster
Start Date
1-3-2019 2:00 PM
End Date
1-3-2019 3:15 PM
Abstract
Breast cancer 1, early onset (BRCA1) is a human tumor suppressor gene encoding the BRCA1 protein that maintains genomic integrity. Molecular events may contribute to the loss of BRCA1 function, contributing to site specific tumorigenesis. Loss of BRCA1 function may arise from mutation or epigenetic events. Germline mutations of BRCA1 have been thoroughly implicated in heritable breast and ovarian cancers. More recently, sporadic breast cancer has been shown to be driven by epigenetic alterations to the BRCA1 promoter region, specifically methylation. Breast carcinomas that present with BRCA1 promoter methylation have been associated with triple negative breast cancers, as well as basal-like breast cancers. Aside from surgical management, targeted chemotherapies are emerging that may target BRCA1 associated tumors effectively. PARP inhibitors and platinum-based chemotherapies are two options that show significant outcomes. The role of BRCA1 methylation may have important clinical implications for BC.
Updates on Epigenetic Alterations to BRCA1: Chemosensitivities
Breast cancer 1, early onset (BRCA1) is a human tumor suppressor gene encoding the BRCA1 protein that maintains genomic integrity. Molecular events may contribute to the loss of BRCA1 function, contributing to site specific tumorigenesis. Loss of BRCA1 function may arise from mutation or epigenetic events. Germline mutations of BRCA1 have been thoroughly implicated in heritable breast and ovarian cancers. More recently, sporadic breast cancer has been shown to be driven by epigenetic alterations to the BRCA1 promoter region, specifically methylation. Breast carcinomas that present with BRCA1 promoter methylation have been associated with triple negative breast cancers, as well as basal-like breast cancers. Aside from surgical management, targeted chemotherapies are emerging that may target BRCA1 associated tumors effectively. PARP inhibitors and platinum-based chemotherapies are two options that show significant outcomes. The role of BRCA1 methylation may have important clinical implications for BC.